Dysuria News and Research

RSS

HPV self-sampling kits via direct mail boost cervical cancer screening rates, study finds

Researchers examined the effectiveness of opt-in and direct-mail strategies for offering self-sampling kits of human papillomavirus (HPV) to populations based on cervical cancer screening history.

28 Nov 2023

Vulvovaginitis and the microbiome: a review of the diagnosis and treatment of acute and recurrent infection

Researchers explored the relationship between microbiome and vulvovaginitis.

11 Apr 2023

Clinical presentation of monkeypox infection in two Israeli males

Researchers described the symptomatology and clinical manifestations of monkeypox infections among two Israeli patients.

12 Jul 2022

Research finds increase in risky sexual behavior and STIs despite COVID-19 pandemic

New research launched at the 29th EADV Congress, EADV Virtual, has found that despite the COVID-19 (SARS-CoV-2) lockdown restrictions, diagnosis of sexually transmitted infections (STIs), including gonorrhoea, secondary syphilis and mycoplasma genitalium (MG), have increased.

2 Nov 2020

NAMS publishes the 2020 Genitourinary Syndrome Of Menopause Position Statement

The North American Menopause Society announces publication of its 2020 Genitourinary Syndrome of Menopause Position Statement.

1 Sep 2020

Blocking key mineral uptake could prevent gonorrhea infection

A team of researchers may have found a way to block gonorrhea infection by blocking bacterial pathogen from using zinc, an essential mineral found in many food sources.

6 Aug 2019

NeoTract presents new clinical data from studies of UroLift System for patients with BPH

NeoTract, a wholly owned subsidiary of Teleflex Incorporated focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from two U.K. studies of the company's novel UroLift System for patients with Benign Prostatic Hyperplasia.

25 Sep 2018

NeoTract announces results of study measuring costs and patient outcomes of UroLift System

NeoTract, a wholly owned subsidiary of Teleflex Incorporated focused on addressing unmet needs in the field of urology, today announced the results of an independent analysis measuring costs and patient outcomes of the UroLift System compared to transurethral resection of the prostate.

8 Jun 2018

AUA recommends use of UroLift System for managing lower urinary tract symptoms attributed to BPH

NeoTract, a wholly owned subsidiary of Teleflex Incorporated focused on addressing unmet needs in the field of urology, today announced that the American Urological Association has recommended the use of the UroLift System as a standard of care treatment for lower urinary tract symptoms due to benign prostatic hyperplasia.

18 May 2018

Cynosure obtains medical device license from Health Canada to market MonaLisa Touch for treatment of GSM symptoms

Cynosure, Inc. today announced that it has received a medical device license issued by Health Canada to market MonaLisa Touch® for the treatment of symptoms related to Genitourinary Syndrome of Menopause (GSM), including vaginal dryness, vaginal burning, vaginal itching, pain, dysuria and dyspareunia.

28 Oct 2015

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ (ceftazidime-avibactam) as a treatment for adult hospitalized patients with complicated urinary tract infections (cUTI), including pyelonephritis.

2 Sep 2015

Postmenopausal women more likely to use vaginal estrogen to achieve significantly higher sexual quality of life

Local vaginal estrogen (VE) appears to have escaped the shroud of doubt cast upon hormone therapy as a result of the Women's Health Initiative Study by providing numerous medical benefits without systemic effects. That's according to a new study reported online today in Menopause, the journal of The North American Menopause Society.

12 Aug 2015

VagiCap improves quality of life, satisfaction for postmenopausal women with vulvar and vaginal atrophy

Newly released patient satisfaction survey results from a study of a novel investigational vaginal estrogen treatment show promise for improving quality of life and satisfaction for postmenopausal women who experience pain during sex and other symptoms associated with vulvar and vaginal atrophy (VVA).

23 Feb 2015

Experts review terminology linked with genitourinary tract symptoms related to menopause

Experts who reviewed the terminology associated with genitourinary tract symptoms related to menopause-currently referred to as vulvovaginal atrophy-have agreed that the term genitourinary syndrome of menopause (GSM) is a medically more accurate, all-encompassing, and a more publicly acceptable term.

3 Sep 2014

LUTS likely to resolve without treatment

Lower urinary tract symptoms in men tend to follow a fluctuating course with marked variability in symptoms over time, a 5-year study has shown.

9 Dec 2013

Quantitative models predict risk of acute urinary symptoms in prostate cancer patients treated with RT

An interim study by Italian researchers showed that using a modelling programme together with IPSS and dosage measure can predict the severity of acute urinary symptoms in patients with early prostate cancer who underwent radiotherapy.

16 Nov 2013

Study shows GreenLight laser therapy effective for BPH treatment

Data presented at the American Urological Association Annual Meeting demonstrate that treatment for Benign Prostatic Hyperplasia with GreenLight XPS laser therapy with MoXy fiber, instead of transurethral resection of the prostate, results in significantly shorter hospitalization, catheterization, and recovery times for patients, while maintaining equivalent safety and efficacy.

4 Jun 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

FDA approves Allergan’s BOTOX to treat overactive bladder

Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

19 Jan 2013

U.S. Marshals seize dietary supplements and unapproved drugs from Confidence

At the request of the U.S. Food and Drug Administration, U.S. Marshals recently seized dietary supplements and unapproved drugs from Confidence, Inc., of Port Washington, N.Y.

24 Oct 2012